This semiquantitative immunohistochemical study investigated the clinical significance of S100A4 and vascular endothelial growth factor C (VEGF-C) protein expression in gastric carcinoma. Correlations between S100A4 and VEGF-C immunoreactivity and clinicopathological characteristics were evaluated using 108 gastric carcinoma specimens and 20 specimens of tissue adjacent to gastric carcinoma. S100A4 and VEGF-C expression in carcinoma was higher than that in adjacent tissues. S100A4 expression was significantly related to tumour size and lymph node metastasis, whereas
Introduction
Gastric carcinoma is one of the most common gastrointestinal malignancies. 1 Although the incidence of gastric cancer has decreased in recent years, 2 -4 it is the second most deadly malignant neoplasm in the world. 5 Worldwide, approximately 876 000 people are diagnosed with this disease every year and approximately 649 000 succumb. 5 In China, gastric carcinoma is one of the most common causes of death from cancer and it leads to approximately 160 000 deaths annually. 6 Gastric carcinomas are usually in an advanced stage (III or IV) with lymph node metastasis when patients present at a hospital. 7 Around 2 -20% of patients with gastric cancer may have lymph node metastasis even at an early stage of the disease. 8 Lymph node metastasis is one of the most L-Z Feng, X-Y Zheng, L-X Zhou et al. Lymph node metastasis, VEGF-C and S100A4 in gastric carcinoma important prognostic factors for gastric carcinoma; 9,10 however, the mechanism of the progression of lymph node metastasis is still unclear. Recent studies have demonstrated a principal role for lymphatic endothelial markers 11, 12 and calciumbinding proteins 13, 14 in the mechanism of tumour invasion and lymphogenous metastasis.
Vascular endothelial growth factor (VEGF) is a mitogen for vascular endothelial cells and an important angiogenesisstimulating factor. 15 Recent studies have demonstrated that VEGF-C is associated with lymphatic spread and invasion of many cancer cells, 15 -18 including gastric carcinoma. 11, 12 S100A4 is a member of the S100 protein family of soluble calciumbinding proteins 19 and is encoded by a metastasis-related gene. 20 S100A4 is highly expressed in many cancers 19, 21, 22 and its presence predicts a poor outcome, such as in pancreatic cancer, 19 colorectal cancer, 21 ovarian carcinoma, 22 bladder carcinoma 23 and oesophageal carcinoma. 24 Only a few studies have investigated the predictive value of S100A4 expression in gastric carcinoma, 13, 14, 25 and the relationships of VEGF-C and S100A4 with clinicopathological parameters and the prognosis of gastric carcinoma are still poorly understood. The relationship between VEGF-C and S100A4 in gastric carcinoma is also unclear. To the best of our knowledge, noone has reported on the protein expression of S100A4 and VEGF-C in gastric carcinoma.
The present study examined protein expression levels of S100A4 and VEGF-C in gastric carcinoma specimens, using immunohistochemistry, and analysed the relationship of S100A4 and VEGF-C expression with clinicopathological parameters such as age, sex and tumour, lymph node, metastasis (TNM) stage.
Patients and methods

PATIENTS AND TISSUE SAMPLES
Specimens of gastric carcinoma tissue were obtained from patients with primary gastric carcinoma who had been admitted to the Department of Surgery, The Second Hospital of Jiaxing City, Jiaxing, China, between 2004 and 2006. Specimens of normal tissue adjacent to the gastric carcinoma (5 mm from the tumour margin), were also taken from some patients for use as a negative control (sufficient to enable statistical significance to be shown). All specimens were fixed in formalin and embedded in paraffin. One representative paraffin block from each specimen was selected for immunohistochemical study. The diagnosis was confirmed after a blinded review of all haematoxylin and eosin stained sections. No patient had received preoperative radiotherapy or chemotherapy. Demographic and clinicopathological data, including sex, age and the T and N categories of the TNM staging system, as established by the 2002 UICC (Union for International Cancer Control) system, 26 were collected retrospectively by reviewing the patients' notes, and a follow-up was undertaken with telephone calls, letters or patient visits with surgeons.
The study protocol was approved by the Institutional Review Board of The Second Hospital of Jiaxing City. Verbal informed consent was given by the patients who provided samples.
IMMUNOHISTOCHEMICAL STAINING AND EVALUATION
Immunohistochemistry was performed on 5 µm thick formalin-fixed, paraffinembedded tissue sections. The sections were first deparaffinized in xylene and rehydrated through graded concentrations of alcohol. For antigen retrieval, endogenous peroxidase L-Z Feng, X-Y Zheng, L-X Zhou et al. Lymph node metastasis, VEGF-C and S100A4 in gastric carcinoma activity was then blocked by incubating the slides in 1.5% hydrogen peroxide in absolute methanol at room temperature for 10 min. Then the slides were immersed in 10 mM citrate buffer (pH 6.0) and heated in a 1200 W microwave oven at the highest power setting for 5 min. Evaporated liquid was then replenished and the samples were then reheated in the microwave, again at the highest setting, for an additional 5 min. Primary antibodies (rabbit monoclonal antibody to VEGF-C [1 : 200 dilution] or rabbit polyclonal antibody to S100A4 [1 : 200 dilution]; Beijing Zhong Shan Biotechnology, Beijing, China) were applied for 1 h at room temperature, according to the manufacturer's instructions, and the sections were washed three times with 0.05 mM phosphate-buffered saline (PBS), pH 7.4. Biotinylated goat antirabbit immunoglobulin G was then applied to the sections, which were incubated for 30 min. They were then incubated for a further 30 min with streptavidin peroxidase. The final complex was visualized by exposing the sections to 0.5 mg/ml 3,3′diaminobenzidine (Beijing Zhong Shan Biotechnology) and 0.005% hydrogen peroxide. After counterstaining with haematoxylin, the sections were dehydrated and evaluated under a light microscope. As a negative control, samples were incubated with 10 mM PBS, pH 7.4, instead of primary antibody.
Specimens showing high expression of VEGF-C or S100A4 were used as positive controls.
The slides were allocated at random for analysis by two experienced pathologists with no knowledge of the clinicopathological data (Y.-W. Y. and S.-C. L.). For each slide, cells positive for VEGF-C or S100A4 were counted and evaluated in 10 fields at × 200 magnification and the percentage of positively staining cells was calculated.
Nuclear and cytoplasmic staining were scored for both proteins as described previously. 12, 13 The percentage of positive cells was graded as follows: grade 0, < 5% positive cells; grade 1, ≥ 5%, < 25%; grade 2, ≥ 25%, < 50%; grade 3, ≥ 50%. Staining intensity was graded according to the following criteria (staining grades): 0, no staining; 1, weak staining (light yellow); 2, moderate staining (yellow-brown); 3, strong staining (brown). The positive cell percentage grade was multiplied by the staining grade, and a product of ≥ 2 was taken to indicate overall immunohistochemical positivity. 18
STATISTICAL ANALYSES
Statistical analyses were conducted using SPSS ® version 13.0 (SPSS Inc., Chicago, IL, USA). A P-value < 0.05 indicated statistical significance. The correlations between VEGF-C and S100A4 expression (i.e. overall immunohistochemical positivity as defined above) and clinicopathological parameters (age, T category and N category) were evaluated with the χ 2 test. Survival curves were plotted using the Kaplan-Meier method. The Spearman test was used to analyse the correlation between VEGF-C and S100A4 expression. Factors with possible prognostic effects in gastric carcinoma were analysed by Cox regression analysis.
Results
CLINICAL CHARACTERISTICS
A total of 108 patients with primary gastric carcinoma had specimens of cancer tissue taken and, in 20 of these, specimens of normal tissue adjacent to the gastric carcinoma (5 mm from the tumour margin), were also taken for use as a negative control. The patients had a median age of 63 years (range 34 -83 years) and comprised 81 males and 27 females. All cases were L-Z Feng, X-Y Zheng, L-X Zhou et al. Lymph node metastasis, VEGF-C and S100A4 in gastric carcinoma diagnosed as primary gastric adenocarcinoma by histopathology; tumours were well differentiated or moderately differentiated in 34 cases and poorly differentiated in 74 cases. All patients underwent curative gastrectomy with lymphadenectomy. The diameters of 57 tumours were < 5 cm and those of 51 tumours were ≥ 5 cm. In 31 patients the tumour had invaded the mucosa and muscularis propria and in 77 patients it had invaded the serosa and outer serosal layer. Seventy-two patients (66.7%) presented with lymph node metastases at the time of diagnosis. The 108 patients were followed up until June 2010 and their median survival time ranged from 1 to 73 months (40 patients died, 57 patients were alive free from disease and 11 patients were lost to follow-up). Details of the patients and their tumours are presented in Table 1 .
EXPRESSION OF S100A4 AND VEGF-C IN GASTRIC CARCINOMA TISSUE
Of 108 gastric carcinoma tissues, 54.6% (59/108) were positive for S100A4 expression ( Fig. 1A ) and 25.0% (5/20) of tissues adjacent to carcinoma were positive for S100A4 (χ 2 = 5.926, P = 0.015) ( Table 2) . VEGF-C protein was detected in 59.3% (64/108) of gastric carcinoma tissues ( Fig. 1B ) and in 35.0% (7/20) of tissues adjacent to carcinoma (χ 2 = 4.021, P = 0.045) ( Table 2) .
RELATIONSHIP BETWEEN S100A4, VEGF-C AND CLINICAL FEATURES
A statistically significant association was found between S100A4 positivity in tumour tissue and tumour size (P = 0.017) and lymph node metastasis (P = 0.02), whereas there was no statistically significant association with sex, age, extent of differentiation, depth of invasion or TNM stage (Table 1) . VEGF-C expression was significantly associated with depth of invasion (P = 0.006), lymph node metastasis (P < 0.027) and TNM stage (P = 0.001). No association was found between VEGF-C and sex, age, tumour size or extent of differentiation.
CORRELATION BETWEEN VEGF-C AND S100A4 EXPRESSION
A total of 69.5% (41/59) of patients who had S100A4-positive tumours also expressed VEGF-C and 53.1% (26/49) S100A4-negative patients did not express VEGF, which gave a significant positive correlation between S100A4 and VEGF-C expression (r = 0.191, P = 0.048).
CORRELATION BETWEEN S100A4 AND VEGF-C EXPRESSION AND PROGNOSIS
Univariate analyses (log rank test) showed that the 5-year survival rate in patients whose tumours expressed S100A4 tended to be lower than that in patients who did not express S100A4 (47.5% versus 59.2%, respectively), although the difference was not statistically significant (Fig. 2) . The 5year survival rate in patients whose tumours expressed VEGF-C also tended to be lower than that in patients who did not (45.3% versus 63.6%, respectively); this difference was also not statistically significant ( Fig. 3) .
Cox regression analysis of factors with possible prognostic effects in gastric carcinoma showed that sex, age, tumour size, invasion depth, lymph node involvement, TNM stage, S100A4 expression and VEGF-C expression had a common effect on the prognosis of gastric carcinoma (χ 2 = 19.661, P = 0.020), however none of these was an independent prognostic factor.
Discussion
The S100A4 protein is one of 24 members of the S100 family. 19, 20 The S100 proteins L-Z Feng, X-Y Zheng, L-X Zhou et al. Lymph node metastasis, VEGF-C and S100A4 in gastric carcinoma L-Z Feng, X-Y Zheng, L-X Zhou et al. Lymph node metastasis, VEGF-C and S100A4 in gastric carcinoma regulate the interaction between Ca 2+ and target proteins. 19, 27 S100A4 is involved in the regulation of a wide range of intracellular and extracellular biological effects, including cell motility, angiogenesis, cell survival, differentiation, contractility and invasion. 13, 27 It has emerged as an important protein with the capacity to promote the invasiveness and metastasis of many human neoplasms. 21 -24 Studies have indicated that S100A4 is associated with tumour invasion and metastasis, and that it may be a potential prognostic marker. 21 -24,27 Kwak et al. 21 detected immunoreactivity for S100A4 in 45 (35.4%) of 127 colorectal cancers and found that S100A4 protein expression was 22 demonstrated that nuclear expression of S100A4 is involved in the aggressive behaviour of ovarian carcinoma and that S100A4 is an autocrine/paracrine factor that plays an important role in the aggressiveness of ovarian carcinoma cells. Matsumoto et al. 28 concluded that S100A4 appears to be an independent predictor of the outcome of treatment of bladder cancer. The expression patterns of S100A4 correlated well with pathological stage, disease progression and cancer-specific mortality. 28 However, there are few corresponding reports for gastric carcinoma. 13, 14, 25, 29 The present study found that significantly more gastric carcinoma tumours than tissue adjacent to carcinoma expressed S100A4. The expression of S100A4 was significantly correlated with tumour size and lymph node metastasis and no significant association was found for S100A4 protein positivity and sex, age, extent of differentiation, depth of invasion or TNM stage. These results were similar to those of Yoon et al. 29 The molecular mechanism of action of S100A4 in tumours is not fully understood. S100A4 may enhance the turnover of myosin IIA filaments at the leading edge of migrating cells, resulting in increased motility, which could contribute to increased metastatic capacity of cancer cells. 27 Matrix metalloproteinases (MMPs) may play an essential role in this process. 27, 30 Slaeem et al. 30 demonstrated that the gene encoding S100A4 controls the invasive potential of human prostate cancer cells by regulating MMP-9 and that this association may contribute to metastasis of human prostate cancer cells. However, the mechanisms by which S100A4 participates in the regulation of MMPs are mostly unknown. 27 
TABLE 2:
Comparison between gastric carcinoma tissue and tissue adjacent to the carcinoma in terms of the expression of S100A4 and vascular endothelial growth factor C (VEGF-C) S100A4 expression L-Z Feng, X-Y Zheng, L-X Zhou et al. Lymph node metastasis, VEGF-C and S100A4 in gastric carcinoma FIGURE 2: Kaplan-Meier curves (log rank test) for patients expressing or not expressing S100A4 showed no statistically significant difference in the cumulative 5year survival rate (47.5% in the group that expressed S100A4 and 59.2% in the group that did not; χ 2 = 1.109) 
VEGF-C expression
Negative expression
Positive expression Lymph node metastasis, VEGF-C and S100A4 in gastric carcinoma
Another important function of S100A4 in tumourigenesis, progression and metastasis is as a potent stimulator of angiogenesis. 27 The mechanisms whereby S100A4 participates in this process are just beginning to be studied. To date, studies have focused on interactions with annexin II 31 and the MMP family. 27 Little attention has been paid to whether S100A4 may affect VEGF, leading to angiogenesis in cancers. 19, 32 Because VEGF also plays an important role in tumour angiogenesis and correlates significantly with tumour invasion and metastasis, 15 -19 we believed that a correlation might exist between S100A4 and VEGF, and this was confirmed in the present study.
In the present study, the relationship between S100A4 and VEGF was analysed in 108 gastric carcinoma specimens using immunohistochemistry. VEGF-C was found to be expressed in 59.3% (64/108) of gastric carcinoma tissues and a positive immunoreaction with VEGF-C was significantly correlated with the depth of invasion, lymph node metastasis and TNM stage. These results suggest that VEGF-C may play an important role in the clinical progression and metastasis of gastric carcinoma. Promotion of tumour metastasis by VEGF-C is reportedly due to the induction of tumour lymphangiogenesis through the effects of activated VEGF receptor-3 (VEGFR-3) on lymphatic endothelial cells. 33 VEGF-C is associated with tumour lymphangio genesis and with the lymphatic spread and invasion of many cancers. 15 -18 However, many undefined functions and molecular mechanisms may be involved in the tumour progression mediated by the VEGF-C/VEGFR-3 axis. 34 Prior to the present study, only two previous studies have reported a correlation between the expression of VEGF and that of S100A4. 19, 32 Using reverse transcription-polymerase chain reaction and Western blot analysis, Moriyama-Kita et al. 32 reported that VEGF-C expression was up-regulated in S100A4-overexpressing clones in oral squamous cell carcinoma. Ai et al. 19 found that S100A4 and VEGF proteins were expressed in pancreatic cancer and demonstrated a close correlation between the expression of the two proteins. These results suggest that S100A4 up-regulates VEGF-C to some degree, however the exact mechanism of the interaction between S100A4 and VEGF-C in gastric carcinoma requires further study at the molecular level.
The TNM stage has been considered to be an important prognostic factor, 13 although TNM stage does not accurately reflect the prognosis of all patients 19 and it was not found to be an independent prognostic factor in the present study. Molecular markers, such as VEGF-C 13,15 -18 and S100A4, 13,19,21 -24 may be independent prognostic factors, but there is disagreement about the value of these as potential prognostic predictors in gastric carcinoma. The present study failed to show any prognostic value of S100A4 expression, however Wang et al. 13 found that S100A4 expression, like lymph node and distant metastases, and TNM stage, may be independent prognostic factors in patients with gastric carcinoma. Yoon et al. 29 also demonstrated that S100A4 may be a useful prognostic marker for individual patients with gastric cancer. In the present study, VEGF-C expression was not associated with a poor prognosis in gastric cancer. Deng et al. 35 reported that VEGF-D expression was a prognostic factor but that VEGF-C expression was not. Wang et al. 36 examined VEGF-C expression in gastric carcinoma tissues of 80 patients using immunohistochemical staining and found that the prognosis was related to serum VEGF-C level, and mean survival time was 34 and 43 months in L-Z Feng, X-Y Zheng, L-X Zhou et al. Lymph node metastasis, VEGF-C and S100A4 in gastric carcinoma groups with tumours showing positive and negative expression of VEGF-C, respectively (P = 0.0001). Thus, further studies are necessary to improve understanding of the prognostic value of the S100A4 protein and VEGF-C in gastric carcinoma.
In conclusion, the present study indicated that the proportion of patients with positive expression for S100A4 and VEGF-C in gastric carcinoma tissues was higher than that in tissues adjacent to the carcinoma. S100A4 expression was also found to be related to lymph node metastasis and VEGF-C expression was associated with invasion depth, lymph node metastasis and clinical stage. A significant correlation was found between S100A4 and VEGF-C expression.
